71 results
SC TO-T
EX-99
BMY
Bristol-Myers Squibb Co.
25 Jan 24
Third party tender offer statement
8:13am
participants in the industries in which RayzeBio operates or the economy generally, as applicable; (vi) any epidemic, pandemic (including COVID-19
424B5
BMY
Bristol-Myers Squibb Co.
1 Nov 23
Prospectus supplement for primary offering
4:16pm
pandemic on our operations; the risk that the approval of Mirati’s stockholders with respect to our proposed acquisition of Mirati may be delayed or may
424B3
BMY
Bristol-Myers Squibb Co.
30 Oct 23
Prospectus supplement
8:05am
of new or revised accounting standards; risks relating to public health outbreaks, epidemics and pandemics, including the impact of the COVID-19 pandemic
8-K
EX-99.1
3pigw
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.1
4s18f0kxrrykn5crub
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.1
wz5fme v99
27 Apr 23
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
7:45am
8-K
EX-99.1
jt5usba
26 Oct 22
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
7:48am
8-K
EX-99.1
m7kh70aq
27 Jul 22
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
7:44am
SC TO-T
EX-99
rntmk1g1o0umr89ovyro
17 Jun 22
Third party tender offer statement
4:42pm
8-K
EX-99.1
wmjzbl
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
8-K
EX-99.2
y45xxg4vrq on8y8
3 Mar 22
Upsizing and Early Settlement of Tender Offers
4:16pm